MARKET

MDGL

MDGL

Madrigal Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

62.82
-2.97
-4.51%
After Hours: 62.82 0 0.00% 16:00 04/07 EDT
OPEN
67.50
PREV CLOSE
65.79
HIGH
68.65
LOW
62.76
VOLUME
219.35K
TURNOVER
--
52 WEEK HIGH
145.16
52 WEEK LOW
56.82
MARKET CAP
969.26M
P/E (TTM)
-11.5241
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MDGL stock price target is 179.83 with a high estimate of 300.00 and a low estimate of 120.00.

EPS

MDGL News

More
  • The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
  • Benzinga · 4d ago
  • FDA Decisions on 5 Drugs Expected in 2nd Quarter
  • GuruFocus.com · 03/30 23:06
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
  • MotleyFool.com · 03/09 15:30

Industry

Biotechnology & Medical Research
-2.89%
Pharmaceuticals & Medical Research
-0.82%

Hot Stocks

Symbol
Price
%Change

About MDGL

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
More

Webull offers kinds of Madrigal Pharmaceuticals Inc stock information, including NASDAQ:MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions.